GLG News by Radiation Oncologists

There is a simple rule of economics. If product A costs $10 to make and sells for $15, the profit is $5. If you outsource your manufacturing to China and get the cost to $5, you make $10. The goal of any for profit business is to make money, and the only way to do that is to cut costs or increase revenue....

Nucletron, arguably the leader in HDR afterloaders now has a 3rd generation machine - the Digital Microselectron.   This unit differs slightly from the very popular 2nd generation  (v2) Microselectron in that it allows scalability in the number of channels availble for source delivery...

Several retail pharmacies and walmart are opening 'urgent care' centers to diagnose and treat patient for low cost, and a short wait. The intention is good, and will likely keep some people from going to the ER.  However, several problems of concern. In the end it's probably a plus for the uninsured...

This news release is significant for analyzing market share of radiation therapy systems as it relates to Varian, Elekta and Tomotherapy

Pristiq has received a letter of approval, but still must undergo some additional safety checks.   The FDA wants evidence that there is not significant adverse cardiac or hepatic events with this drug, and is asking for a randomized trial to prove it. Since the trial must have at least a year of...

Satraplatin, and oral platinum based chemotherapy is under investigation in several applications including hormone refractory prostate cancer, and lung cancer. The SPARC trial (Satraplatin and Prednisone Against Refractory Cancer), evaluating Satraplatin plus prednisone vs. placebo has randomized...

Antibodies against CD44 are an interesting and novel idea in treating cancers.   Arius has theorized that cancer stem cells, which can survive cytotoxic treatment can be identified and targed for cell death via a CD44 antibody.   Preclinical models have demonstrated potent inhibition...

Chemotherapy induced peripheral neuropathy is a big problem in the management of many common cancers.  In particular, taxane base regimens (used in breast and lung cancer), and oxaliplatin (used in colorectal cancers) have reasonable rates of peripheral neuropathy.   While many patients...

We have a major probelm in our healthcare system, and it has to do with declining reimbursements and increasing overhead.   Small physician practices are learning that the only way to remain competitive is to increase throughput of patients, thus shortening encounters, and dealing with fewer...

The data from the STAR P-2 trial on tamoxifen vs. raloxifene show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease. This very large trial...